+ Watch KYTH
on My Watchlist
Insiders starting to sell shares on the open market, so what I call the "honeymoon" phase of the IPO cycle is probably over for this stock. I coined that phrase in some blog posts last year.
My disastrous flirtation with FibroCell tells me I don't know much about the market for cosmetic therapies, but I'll hazard a green thumb on Kythera ahead of the topline data from the phase III trials of ATX-101 in chin fat. The two European phase III trials have already been reported as positive, which indicates to me that the data is likely to be good. The share price was over 30 at the beginning of the year but the stock couldn't maintain the upward momentum. Despite the lofty share price, the market cap is just a little over 400M.I wouldn't risk real money here, and sadly Kythera is too young as a public company to have an options market established, so this will remain a virtual play.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions